Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cellebrite DI Ltd. before investing.

In this article, we go over a few key elements for understanding Cellebrite DI Ltd.’s stock price such as:

• Cellebrite DI Ltd.’s current stock price and volume
• Why Cellebrite DI Ltd.’s stock price changed recently
• Upgrades and downgrades for CLBT from analysts
• CLBT’s stock price momentum as measured by its relative strength

About Cellebrite DI Ltd. (CLBT)

Before we jump into Cellebrite DI Ltd.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.

Want to learn more about Cellebrite DI Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cellebrite DI Ltd..

Cellebrite DI Ltd.’s Stock Price as of Market Close

As of June 23, 2026, 4:00 PM, CST, Cellebrite DI Ltd.’s stock price was $12.740.

Cellebrite DI Ltd. is up 2.58% from its previous closing price of $12.420.

During the last market session, Cellebrite DI Ltd.’s stock traded between $12.410 and $12.920. Currently, there are approximately 245.28 million shares outstanding for Cellebrite DI Ltd..

Cellebrite DI Ltd.’s price-earnings (P/E) ratio is currently at 41.1, which is high compared to the Software industry median of 29.3. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Cellebrite DI Ltd. Stock Price History

Cellebrite DI Ltd.’s (CLBT) price is currently down 13.51% so far this month.

During the month of June, Cellebrite DI Ltd.’s stock price has reached a high of $16.110 and a low of $12.165.

Over the last year, Cellebrite DI Ltd. has hit prices as high as $19.980 and as low as $11.020. Year to date, Cellebrite DI Ltd.’s stock is down 29.34%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cellebrite DI Ltd. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 23, 2026, there was 1 analyst who downgraded Cellebrite DI Ltd.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Cellebrite DI Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cellebrite DI Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Cellebrite DI Ltd.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cellebrite DI Ltd. (CLBT) by visiting AAII Stock Evaluator.

Relative Price Strength of Cellebrite DI Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 23, 2026, Cellebrite DI Ltd. has a weighted four-quarter relative price strength of -11.60%, which translates to a Momentum Score of 22 and is considered to be Weak.

Want to learn more about how Cellebrite DI Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cellebrite DI Ltd. Stock Price: Bottom Line

As of June 23, 2026, Cellebrite DI Ltd.’s stock price is $12.740, which is up 2.58% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cellebrite DI Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.